The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
ARQ 087, an oral pan-fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with advanced intrahepatic cholangiocarcinoma (iCCA) with FGFR2 genetic aberrations.
 
Vincenzo Mazzaferro
Honoraria - Bayer
Consulting or Advisory Role - Bayer
Speakers' Bureau - Bayer; BTG
Travel, Accommodations, Expenses - BTG
 
Bassel F. El-Rayes
Consulting or Advisory Role - BTG; Merrimack
Research Funding - AVEO; Boston Biomedical; Bristol-Myers Squibb; Cleave Biosciences; Genentech; Novartis; Taiho Pharmaceutical
 
Christian Cotsoglou
No Relationships to Disclose
 
William Proctor Harris
Consulting or Advisory Role - Neo Therma
Research Funding - ArQule (Inst); Exelixis (Inst); Halozyme (Inst); Nordion (Inst); Polaris (Inst)
Travel, Accommodations, Expenses - Halozyme
 
Nevena Damjanov
Honoraria - Daiichi Sankyo (I); Sirtex Medical
Consulting or Advisory Role - Amgen; Bayer; Celgene
 
Gianluca Masi
No Relationships to Disclose
 
Lorenza Rimassa
Consulting or Advisory Role - Bayer; Italfarmaco; Lilly; Sirtex Medical
Travel, Accommodations, Expenses - ArQule
Other Relationship - Amgen
 
Nicola Personeni
No Relationships to Disclose
 
Fadi S. Braiteh
Stock and Other Ownership Interests - Agios; Bristol-Myers Squibb; Clovis Oncology; Insys Therapeutics; Tesaro
Honoraria - Abbott Nutrition; Amgen; ARIAD; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Genentech/Roche; HERON; Incyte; Insys Therapeutics; Insys Therapeutics; Ipsen; Lexicon; Lilly; Taiho Pharmaceutical
Consulting or Advisory Role - Ambry Genetics; Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Clovis Oncology; Genentech/Roche; Incyte; Insys Therapeutics; Ipsen; Ipsen; Lexicon; Lilly; Merck; Merrimack; Pfizer; Regeneron; Sanofi
Speakers' Bureau - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Genentech/Roche; Incyte; Insys Therapeutics; Ipsen; Lilly; Merck; Merck; Merrimack; Pfizer; Taiho Pharmaceutical
Travel, Accommodations, Expenses - Amgen; AstraZeneca/MedImmune; Bayer; Bayer/Onyx; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Clovis Oncology; Exelixis; HERON; Incyte; Insys Therapeutics; Ipsen; Lexicon; Merrimack; Novartis; Pfizer; Regeneron; Roche/Genentech; Sanofi; Taiho Pharmaceutical; Tesaro
 
Vittorina Zagonel
No Relationships to Disclose
 
Kyriakos P. Papadopoulos
Research Funding - Abbvie (Inst); Amgen (Inst); ARMO BioSciences (Inst); ArQule (Inst); Calithera Biosciences (Inst); Curegenix (Inst); Daiichi Sankyo (Inst); GlaxoSmithKline (Inst); Incyte (Inst); MedImmune (Inst); Merck (Inst); Novartis (Inst); Onyx (Inst); Peloton Therapeutics (Inst); Regeneron (Inst); Sanofi (Inst)
 
Terence Hall
Employment - ArQule
Stock and Other Ownership Interests - ArQule
 
Yunxia Wang
Employment - ArQule
Stock and Other Ownership Interests - ArQule
 
Giovanni Abbadessa
Employment - Alexion Pharmaceuticals (I); ArQule; Biogen (I)
Stock and Other Ownership Interests - Alexion Pharmaceuticals (I); ArQule; Biogen (I)
Patents, Royalties, Other Intellectual Property - ArQule
 
Brian E. Schwartz
Employment - ArQule
Leadership - ArQule
Stock and Other Ownership Interests - ArQule
Honoraria - California Institute for Regenerative Medicine (CIRM)
Consulting or Advisory Role - California Institute for Regenerative Medicine (CIRM)
 
Julia Kazakin
Employment - ArQule
Stock and Other Ownership Interests - ArQule
 
Michele Droz Dit Busset
No Relationships to Disclose
 
Walid Labib Shaib
No Relationships to Disclose